 PDUFA date with Priority Review for mirvetuximab for treatment of ovarian cancer patients with high folate receptor alpha set for November 28, 2022. Confirmatory MIRASOL study trial readout of mirvetuximab for treatment of ovarian cancer patients with high folate receptor alpha expected early 2023. 